Freestone Grove Partners LP Altimmune, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 14,418 shares of ALT stock, worth $97,754. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,418Holding current value
$97,754% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALT
# of Institutions
209Shares Held
39.5MCall Options Held
1.94MPut Options Held
1.38M-
Black Rock Inc. New York, NY5.32MShares$36.1 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN5.25MShares$35.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.43MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.47MShares$23.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.6 Million1.49% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $332M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...